256 related articles for article (PubMed ID: 12081987)
1. Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study.
Mitchell GF; Izzo JL; Lacourcière Y; Ouellet JP; Neutel J; Qian C; Kerwin LJ; Block AJ; Pfeffer MA
Circulation; 2002 Jun; 105(25):2955-61. PubMed ID: 12081987
[TBL] [Abstract][Full Text] [Related]
2. Changes in aortic stiffness and augmentation index after acute converting enzyme or vasopeptidase inhibition.
Mitchell GF; Lacourcière Y; Arnold JM; Dunlap ME; Conlin PR; Izzo JL
Hypertension; 2005 Nov; 46(5):1111-7. PubMed ID: 16230523
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats.
Kostova E; Jovanoska E; Zafirov D; Jakovski K; Maleska V; Slaninka-Miceska M
Bratisl Lek Listy; 2005; 106(12):407-11. PubMed ID: 16642666
[TBL] [Abstract][Full Text] [Related]
4. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial.
Kostis JB; Packer M; Black HR; Schmieder R; Henry D; Levy E
Am J Hypertens; 2004 Feb; 17(2):103-11. PubMed ID: 14751650
[TBL] [Abstract][Full Text] [Related]
5. Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats.
Pu Q; Touyz RM; Schiffrin EL
J Hypertens; 2002 May; 20(5):899-907. PubMed ID: 12011651
[TBL] [Abstract][Full Text] [Related]
6. Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients.
Campese VM; Lasseter KC; Ferrario CM; Smith WB; Ruddy MC; Grim CE; Smith RD; Vargas R; Habashy MF; Vesterqvist O; Delaney CL; Liao WC
Hypertension; 2001 Dec; 38(6):1342-8. PubMed ID: 11751715
[TBL] [Abstract][Full Text] [Related]
7. Effects of omapatrilat in low, normal, and high renin experimental hypertension.
Trippodo NC; Robl JA; Asaad MM; Fox M; Panchal BC; Schaeffer TR
Am J Hypertens; 1998 Mar; 11(3 Pt 1):363-72. PubMed ID: 9544878
[TBL] [Abstract][Full Text] [Related]
8. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).
Packer M; Califf RM; Konstam MA; Krum H; McMurray JJ; Rouleau JL; Swedberg K
Circulation; 2002 Aug; 106(8):920-6. PubMed ID: 12186794
[TBL] [Abstract][Full Text] [Related]
9. Antihypertensive and antihypertrophic effects of omapatrilat in SHR.
Burrell LM; Droogh J; Man in't Veld O; Rockell MD; Farina NK; Johnston CI
Am J Hypertens; 2000 Oct; 13(10):1110-6. PubMed ID: 11041166
[TBL] [Abstract][Full Text] [Related]
10. Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension.
Quaschning T; d'Uscio LV; Shaw S; Lüscher TF
Hypertension; 2001 Apr; 37(4):1108-13. PubMed ID: 11304511
[TBL] [Abstract][Full Text] [Related]
11. Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects.
McClean DR; Ikram H; Mehta S; Heywood JT; Rousseau MF; Niederman AL; Sequeira RF; Fleck E; Singh SN; Coutu B; Hanrath P; Komajda M; Bryson CC; Qian C; Hanyok JJ;
J Am Coll Cardiol; 2002 Jun; 39(12):2034-41. PubMed ID: 12084605
[TBL] [Abstract][Full Text] [Related]
12. Vasopeptidase inhibition: a new concept in blood pressure management.
Burnett JC
J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
[TBL] [Abstract][Full Text] [Related]
13. Influence of antihypertensive therapy with cilazapril and hydrochlorothiazide on the stiffness of the aorta.
Breithaupt-Grögler K; Leschinger M; Belz GG; Butzer R; Erb K; de May C; Sinn W
Cardiovasc Drugs Ther; 1996 Mar; 10(1):49-57. PubMed ID: 8723170
[TBL] [Abstract][Full Text] [Related]
14. Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension.
Ferrario CM; Smith RD; Brosnihan B; Chappell MC; Campese VM; Vesterqvist O; Liao WC; Ruddy MC; Grim CE
Am J Hypertens; 2002 Jun; 15(6):557-64. PubMed ID: 12074359
[TBL] [Abstract][Full Text] [Related]
15. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
Solomon SD; Skali H; Bourgoun M; Fang J; Ghali JK; Martelet M; Wojciechowski D; Ansmite B; Skards J; Laks T; Henry D; Packer M; Pfeffer MA;
Am Heart J; 2005 Aug; 150(2):257-62. PubMed ID: 16086927
[TBL] [Abstract][Full Text] [Related]
16. Omapatrilat--the story of Overture and Octave.
Coats AJ
Int J Cardiol; 2002 Nov; 86(1):1-4. PubMed ID: 12243845
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamic and humoral effects of vasopeptidase inhibition in canine hypertension.
Maniu CV; Meyer DM; Redfield MM
Hypertension; 2002 Oct; 40(4):528-34. PubMed ID: 12364358
[TBL] [Abstract][Full Text] [Related]
18. Recent clinical trials with omapatrilat: new developments.
Zanchi A; Maillard M; Burnier M
Curr Hypertens Rep; 2003 Aug; 5(4):346-52. PubMed ID: 12844471
[TBL] [Abstract][Full Text] [Related]
19. Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats.
Pu Q; Amiri F; Gannon P; Schiffrin EL
J Hypertens; 2005 Feb; 23(2):401-9. PubMed ID: 15662229
[TBL] [Abstract][Full Text] [Related]
20. Cardiorenal protective effects of vasopeptidase inhibition with omapatrilat in hypertensive transgenic (mREN-2)27 rats.
Mifsud SA; Burrell LM; Kubota E; Jaworski K; Cooper ME; Wilkinson-Berka JL
Clin Exp Hypertens; 2004 Jan; 26(1):69-80. PubMed ID: 15000298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
